I&I startup Attovia files to go public as biotech listings momentum builds

Attovia Therapeutics, a clinical-stage biopharmaceutical company focused on immune-mediated and inflammatory (I&I) diseases, filed an S-1 registration statement with the U.S. Securities and Exchange Commission on July 14, 2026, to pursue an initial public offering (IPO) on the Nasdaq Global Market under the ticker symbol "ATTO." The company aims to raise up to $100 million through the offering, building on over $255 million in prior private funding from investors including Frazier Life Sciences, Deep Track Capital, Goldman Sachs, and venBio. Attovia is advancing an IL-31–targeting pipeline led by ATTO-1310, a fusion protein for chronic pruritus and high-itch atopic dermatitis, alongside bispecific and trispecific candidates in preclinical development. The filing arrives amid a strong 2026 biotech IPO environment, with Attovia and Braveheart Bio among the latest wave of startups signaling readiness to list as investor appetite for immunology and platform-driven biotechs improves.